- Home
- ASTC vs KPRX Comparison
ASTC vs KPRX Comparison
Compare ASTC & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTC
- KPRX
- Stock Information
- Founded
- ASTC 1984
- KPRX 1998
- Country
- ASTC United States
- KPRX United States
- Employees
- ASTC N/A
- KPRX N/A
- Industry
- ASTC Biotechnology: Laboratory Analytical Instruments
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ASTC Industrials
- KPRX Health Care
- Exchange
- ASTC Nasdaq
- KPRX Nasdaq
- Market Cap
- ASTC 11.9M
- KPRX 11.0M
- IPO Year
- ASTC 1995
- KPRX N/A
- Fundamental
- Price
- ASTC $7.70
- KPRX $3.37
- Analyst Decision
- ASTC
- KPRX Strong Buy
- Analyst Count
- ASTC 0
- KPRX 1
- Target Price
- ASTC N/A
- KPRX $10.00
- AVG Volume (30 Days)
- ASTC 17.7K
- KPRX 45.5K
- Earning Date
- ASTC 11-12-2024
- KPRX 12-03-2024
- Dividend Yield
- ASTC N/A
- KPRX N/A
- EPS Growth
- ASTC N/A
- KPRX N/A
- EPS
- ASTC N/A
- KPRX 1.69
- Revenue
- ASTC $1,273,000.00
- KPRX $16,020,000.00
- Revenue This Year
- ASTC N/A
- KPRX N/A
- Revenue Next Year
- ASTC N/A
- KPRX N/A
- P/E Ratio
- ASTC N/A
- KPRX $1.99
- Revenue Growth
- ASTC 11.96
- KPRX N/A
- 52 Week Low
- ASTC $6.56
- KPRX $3.00
- 52 Week High
- ASTC $12.29
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- ASTC 56.01
- KPRX 46.21
- Support Level
- ASTC $6.99
- KPRX $3.20
- Resistance Level
- ASTC $7.47
- KPRX $3.49
- Average True Range (ATR)
- ASTC 0.44
- KPRX 0.19
- MACD
- ASTC 0.12
- KPRX -0.03
- Stochastic Oscillator
- ASTC 86.36
- KPRX 32.66
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.